177583-70-9

Basic information

• Product Name: 2-(4-HYDROXYPHENYL)-3-METHYL-1-[10-(PENTYLSULFONYL)DECYL]-1H-INDOL-5-OL
• Synonyms: 2-(4-HYDROXYPHENYL)-3-METHYL-1-[10-(PENTYLSULFONYL)DECYL]-1H-INDOL-5-OL;ZK 164015
• CAS NO: 177583-70-9
• Molecular Formula: C30H43NO4S
• Molecular Weight: 513.73
• Mol File: 177583-70-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 712.4°Cat760mmHg
• Flash Point: 384.6°C
• Appearance: /
• Density: 1.13g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Store at RT
• CAS DataBase Reference: 2-(4-HYDROXYPHENYL)-3-METHYL-1-[10-(PENTYLSULFONYL)DECYL]-1H-INDOL-5-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-HYDROXYPHENYL)-3-METHYL-1-[10-(PENTYLSULFONYL)DECYL]-1H-INDOL-5-OL(177583-70-9)
• EPA Substance Registry System: 2-(4-HYDROXYPHENYL)-3-METHYL-1-[10-(PENTYLSULFONYL)DECYL]-1H-INDOL-5-OL(177583-70-9)

Safety Data

• Hazardous Substances Data: 177583-70-9(Hazardous Substances Data)

Usage

Uses

ZK 164015 is a potent ER silent antagonist.

Biological Activity

Potent estrogen receptor silent antagonist. Inhibits 17b-estradiol stimulation of luciferase activity (IC 50 = 0.025 mM) and potently inhibits the growth of estrogen-sensitive human MCF-7 breast cancer cells in vitro (IC 50 ~ 1 nM).

InChI:InChI=1/C30H43NO4S/c1-3-4-12-21-36(34,35)22-13-10-8-6-5-7-9-11-20-31-29-19-18-27(33)23-28(29)24(2)30(31)25-14-16-26(32)17-15-25/h14-19,23,32-33H,3-13,20-22H2,1-2H3

Relevant articles and documents

2-phenylindoles as antiestrogenic pharmaceutical agents

PCT No. PCT/EP95/03000 Sec. 371 Date May 14, 1997 Sec. 102(e) Date May 14, 1997 PCT Filed Jul. 27, 1995 PCT Pub. No. WO96/03375 PCT Pub. Date Feb. 8, 1996Novel 2-phenyl indoles are disclosed of general formula (I), wherein: R1 represents one of the rests -(CH2)n-S(O)m-R4, -(CH2)n-NR6-SO2-R4, (a), and n' being integers between 4 and 12 and m and m' are 0, 1 or 2; X represents a methylene group, an imino group =NR6, or an oxygen or sulphur atom; R2 and R3 independently of one another represent a hydrogen atom, a C1-C10 alkyl group, a benzyl, alkanoyl or alkanoyloxy, or carbarnoyl rest of formula -C(O)R5 or -C(O)NR6R7 or a tetrahydropyranyl group; R4 represents a hydrogen atom, a C1-C10 alkyl, a completely or partially fluorinated alkyl group -(CH2)o-(CF2)pCF3, o and p being independently of one another integers between 0 and 6, an (alkyl)amino or (alkyl)carbamoyl group of formula (CH2)q-Y-NR8R9, q being an integer between 0 and 6 and Y representing a direct bond, a methylene or carbamoyl group (a condition being that q cannot be 0 when Y is a carbonyl group and m is 2), an aryl, aralkyl or heteroaryl group; R5 represents a C1-C10 alkyl group or a C1-C10 alkoxy group, a phenyl or benzyl group; R6, R7, R8 and R9 independently of one another represent a hydrogen atom, a C1-C10 alkyl group, or a benzyl group; and R10 represents a methyl group and R11 represents a hydrogen atom, or R10 and R11 both represent a di-, tri- or tetramethylene bridge which can also have a C-C double bond at any location in the bridge. These novel compounds have strong and selective anti-oestrogen properties and are suitable for use in particular in the treatment of oestrogen-related diseases.